BioLineRx Ltd. (BLRX)

NASDAQ: BLRX · IEX Real-Time Price · USD
1.44
0.20 (16.13%)
May 26, 2022 3:59 PM EDT - Market closed

Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.

The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.

The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.
BioLineRx Logo
CountryIsrael
Founded2003
IPO DateJul 25, 2011
IndustryBiotechnology
SectorHealth Care
Employees38
CEOPhilip Serlin

Contact Details

Address:
Modi'in Technology Park
2 Hamaayan Street, Modiin 7177871
Israel
Phone972 8 642 9100
Websitebiolinerx.com

Stock Details

Ticker SymbolBLRX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001498403

Key Executives

NamePosition
Philip A. Serlin CPA, M.B.A., CPA, MBAChief Executive Officer
Mali Zeevi CPA, CPAChief Financial Officer
Dr. Ella SoraniChief Development Officer
Dr. Abi Vainstein-Haras M.D.Chief Medical Officer
Advocate Norman KotlerInternal Enforcement Officer, General Counsel and Corporate Secretary
Liron Shemesh-Darvish M.B.A., Ph.D.Senior Director and Head of Preclinical Development
Jael Birenberg M.Sc.Senior Director and Head of RA, QA and PhV
Tsipi Keren-Lehrer B.Sc., L.L.B.Head of BD and Strategic Advisor
Raziel FriedTreasurer and Budgetary Control Director
Dr. Leah N KlapperConsultant

Latest SEC Filings

DateTypeTitle
May 11, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 16, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Mar 16, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 3, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Feb 11, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 24, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jan 18, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 17, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 15, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 3, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings